MUC1 and neoplasm: showed that the C595scFv-Fc-IL2 fusion protein, by binding to MUC1, activates NK cells and enhances their ability to kill MUC1-positive tumor cells, indicating positive implications for clinical treatment of MUC1-positive tumors (140).